CAMBRIDGE, England – Respiratory solutions provider GSK will incorporate a breath biopsy platform from Owlstone Medical into the development of a drug in its respiratory disease pipeline. Owlstone Medical’s Breath Biopsy platform analyzes biomarkers from breath and has the potential to generate data needed to improve clinical outcomes and reduce health care costs. “We believe that the non-invasive Breath Biopsy can rapidly establish a central role in a variety of precision medicine applications such as patient stratification and monitoring treatment response,” said Billy Boyle, co-founder and CEO at Owlstone Medical, in a statement. “We intend to work with multiple pharmaceutical partners looking to optimize the health economic impact of their new medicines across a broad range of diseases by providing access to the data needed to ensure that the right therapy is given to the right patient at the right time.” GSK will use the platform as part of a Phase II clinical trial to assess whether the right patient for the right treatment can be identified, as well as to assess the treatment effects of a novel drug for chronic obstructive pulmonary disease.
You are here: / / GSK taps Owlstone Medical’s Breath Biopsy platform for drug development trial